ANN ARBOR -- Everist Genomics, a developer of personalized medicine, announced the publication of positive results from an international validation study which demonstrated that the OncoDefender-CRC ...
ACG has issued a statement urging clinicians to interpret American Cancer Society’s revised colorectal cancer screening ...
Thomas J Catalano is a CFP and Registered Investment Adviser with the state of South Carolina, where he launched his own financial advisory firm in 2018. Thomas' experience gives him expertise in a ...
Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...
The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...
– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is ...
CRC screening rates in a large managed care organization were low. Among those screened, use was associated more with physicians' recommendations than with patient preferences. Multi-method study ...
Morgantown-based West Virginia University Cancer Institute researchers are assessing a novel blood test for detecting colorectal cancer. 1. The recently FDA-approved blood test screens for an abnormal ...
Please provide your email address to receive an email when new articles are posted on . A novel screening kit for colorectal cancer that uses the immunochromatographic fecal tumor M2 pyruvate kinase ...
WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...
Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People
MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results